GPs to Receive Financial Incentives for Weight-Loss Drug Prescriptions
The Department of Health and Social Care has announced a new initiative offering financial bonuses to general practitioners to accelerate the rollout of weight-loss medications within the NHS. This move comes eight months after the health service introduced these drugs, amid concerns over uneven access across the country.
Addressing Disparities in Patient Access
Health Secretary Wes Streeting has pledged to make weight-loss jabs available "to the many, not the few", highlighting that not all GP practices currently prescribe these drugs. This has led to significant regional disparities, with an estimated 2.4 million people in the UK taking weight-loss medications, most of whom access treatment privately due to NHS limitations.
The government's response includes a £25 million funding package, integrated into a new GP contract, designed to incentivise family doctors to prescribe these medications and refer eligible patients to specialised weight management services. Streeting emphasised that access should be based on clinical need rather than financial capability, noting the risks associated with private prescriptions and unlicensed drugs.
Phased Rollout and Eligibility Criteria
NHS England has implemented a phased rollout plan for medications like Mounjaro over up to 12 years, with strict eligibility criteria initially targeting severely obese individuals with additional health complications. Approximately 220,000 patients have been prioritised in the first three years, but current data indicates that even eligible patients face challenges in obtaining the drug through the NHS.
If all eligible patients—estimated at over three million—sought treatment in the first year, with 70% starting therapy, it could occupy 18% of GP appointments, underscoring the workload concerns previously raised by leading GPs. Research also suggests that private prescription uptake is dominated by women and middle-class individuals, further highlighting access inequalities.
Broader Public Health and Economic Goals
Streeting framed this initiative as part of a wider public health strategy to alleviate the £11 billion burden obesity places on the NHS and the economy. The new incentives aim to embed fairness into the obesity jab rollout, ensuring phased access for those with the highest clinical needs first. This approach seeks to mitigate the proliferation of rogue prescribers and dangerous unlicensed drugs in the private market, while improving equitable patient support across the nation.
